(SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently ...
GlobalData on MSN1d
Santhera launches DMD therapy in the UK following NICE nodNICE’s positive final guidance for Agamree follows confirmation that no appeals were submitted against its positive December ...
Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarterPratteln, Switzerland, January 16, 2025 – ...
Santhera Pharmaceuticals’ Agamree (vamorolone) has been accepted by the Scottish Medicines Consortium (SMC) to treat Duchenne ...
Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...
Santhera Pharmaceuticals said that it received positive recommendation from the Scottish Medicines Consortium for use of AGAMREE ...
(RTTNews) - Santhera Pharmaceuticals said that it received positive recommendation from the Scottish Medicines Consortium for use of AGAMREE (Vamorolone) within NHS Scotland for the treatment of ...
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on January 8. Read why I rate ...
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company, announces that the Scottish Medicines Consortium (SMC) has published recommendations that Agamree (vamorolone) is accepted for use ...
The Scottish Medicines Consortium (SMC) approved the drugs for use by NHS Scotland.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback